Global Lymphoma Therapeutics Market
Sizing, Segmentation, & Growth Forecast (2025-2030)
Last updated: July 2026
Report Scope: The downloadable datasheet contains market sizes in USD for the period 2025-30.
Market Breakdown: Sizes and growth rates are broken down by geography and market segment (see below for details).
1. Summary
The Global Lymphoma Therapeutics Market was valued at $20.1 bn. in 2025. During the forecast period 2025-2030, it is expected to grow at 8.4% CAGR, to an estimated market size of $30.2 bn. in 2030. A detailed breakdown by segment and geography is provided in the downloadable datasheet.
2. Market Definition
The global lymphoma therapeutics market encompasses the development, manufacturing, and distribution of pharmaceutical treatments for Hodgkin Lymphoma (HL) and Non-Hodgkin Lymphoma (NHL). The scope includes various treatment modalities such as immunotherapy, targeted therapy, chemotherapy, radiation therapy, and advanced CAR-T cell therapies, while excluding general supportive care and non-oncological lymphatic treatments.
3. Trends & Demand Drivers
Several key trends are expected to significantly impact the Lymphoma Therapeutics Market in the period 2025-30:
- The rising global incidence of lymphoma is primarily driven by an aging population, as the median age for diagnosis is approximately 67 years.
- There is a significant shift toward precision medicine and personalized treatment plans based on specific genetic mutations and biomarkers.
- The rapid adoption of CAR-T cell therapy and bispecific antibodies is transforming the treatment landscape for relapsed or refractory cases.
- Integration of Artificial Intelligence (AI) is enhancing early diagnosis, optimizing individualized treatment protocols, and accelerating drug discovery.
- The high cost of novel therapeutics remains a major restraint, creating financial strain on healthcare systems and limiting patient access in developing regions.
- Increased R&D investment and a robust clinical trial pipeline are leading to the approval of next-generation antibody-drug conjugates (ADCs).
- The Asia-Pacific region is emerging as a high-growth market due to improving healthcare infrastructure and increased diagnostic capabilities.
4. Market Breakdown
The downloadable datasheet breaks market sizes and growth rates (CAGRs) down into the following geographies and segments:
Geographies
- North America
- Europe
- Asia-Pacific
- Rest of World
Segments
- Non-Hodgkin Lymphoma (NHL)
- Hodgkin Lymphoma (HL)